Longenesis announced today that a study on type 1 diabetes care, in partnership with Medtronic (NYSE:MDT), supports insulin pump use.
Across less than three months, more than 85 patients participated in the research study aimed at providing qualitative and quantitative data on the quality of life for type 1 diabetics using insulin pumps compared to daily insulin injections.
Study sponsors used participant data to evaluate the efficiency of local reimbursement policies for insulin pumps and glucose monitors to help create more informed and patient-centric policies, according to a news release.
The data demonstrated that insulin pump use supports a higher quality of life, with cost representing the main reason to avoid or stop insulin pump usage, emphasizing the importance of patient-centric reimbursement policies for diabetes patients, Longenesis said.
Longenesis and Medtronic initially partnered last year to study diabetic patients’ quality of life, using Longenesis’ engagement tools to ensure dynamic patient identification, efficient digital onboarding and follow-up communication.
“Preparation and execution of type 1 diabetes research and advocacy project is Medtronic’s first cooperation with Longenesis,” a representative from the Medtronic Baltic office said in the release. “We highly value the professional attitude, friendly communication, and efficient and quick work of the team to prepare and execute the research project. The digital approach and tools used by Longenesis for this project have greatly impacted the speed of patient enrolment, are easy to use and comply with the highest standards of safety, data protection and patient-centric approaches.”
Approximately 80% of patients in the study reviewed their participation as satisfactory, with no patients expressing dissatisfaction, according to Longenesis. Results of the study are currently in pre-print for a number of journals and were presented as part of the European Congress of Endocrinology.
The project findings will serve as a tool for patient advocacy groups and respective stakeholders in drawing the government’s attention to the needs of type 1 diabetes patients in managing their care, both financially and personally, Longenesis said.